Affiliated with a Castle Connolly Top Hospital
Who is Dr. Mitchell, Hematologist in Stanford, CA?
Dr. Beverly Mitchell, MD is a Hematologist, who primarily practices in Stanford, CA with 1 additional practice location. She is board certified. Dr. Mitchell completed her residency at University of Washington. Dr. Mitchell is fluent in English, and is currently seeing new patients. Dr. Mitchell’s practice accepts Aetna, Cigna, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Mitchell’s office at (650) 498-5710.
What are Areas of Expertise for Dr. Mitchell?
Dr. Beverly Mitchell, MD is a highly-rated, board-certified Hematologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Mitchell empowers patients to confidently navigate their health journey, specializing in Hematologic Malignancies, Leukemia & Lymphoma, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Mitchell is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Mitchell go to medical school and complete their residency?
Fellowship: University of Michigan Hospital
Residency: University of Washington
Is Dr. Mitchell board certified as a Hematologist?
Yes, Dr. Beverly Mitchell, MD is board certified by the American Board of Internal Medicine since 1978, American Board of Internal Medicine since 1973
What languages does Dr. Mitchell speak?
Dr. Mitchell and their clinical team can communicate with patients in the following languages:
English
What conditions does a Hematologist like Dr. Mitchell typically treat?
As a Hematologist, conditions treated by Dr. Beverly Mitchell may include:
Please contact Dr. Mitchell's office directly to confirm care for your specific condition, for more information, or to schedule a consultation.
What procedures does a Hematologist like Dr. Mitchell typically perform?
As a Hematologist, procedures performed by Dr. Beverly Mitchell may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
Please contact Dr. Mitchell's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Mitchell accept my insurance?
Dr. Mitchell accepts most major insurance plans. Important: Please call our office at (650) 498-5710 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Mitchell accept in Stanford, CA?
Dr. Mitchell in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Aetna
Blue Cross Blue Shield
Blue Cross Blue Shield of Illinois
Blue Cross Blue Shield of Michigan
Capital Blue Cross
Cigna
Elevance Health Inc. (formerly Anthem)
Harvard Pilgrim
Oscar
Oxford Health Plans
View All Insurances
Where is Dr. Mitchell's office located?
Recognitions
Publications
Reduced rR expression and increased rD promoter methylation in CD34
, 2012
Reactive Oxygen Species Regulate Nucleostemin Oligomerization and Protein Degradation
, 2011
Determints of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H
, 2008
Guanine nucleotide depletion inhibits pre-ribosomal R synthesis and causes nucleolar proteins
, 2008
Phase I study of 506U78 administered on a consecutive 5-day schedule in children
, 2005
ACCO: ASCO core curriculum outline
, 2005
Effects of the IMP-dehydrogese inhibitor, Tiazofurin
, 2004
Role of human Pso4 in mammalian D repair and association with termil deoxynucleotidyl transferase
, 2003
Sequential azacitidine plus lelidomide combition
, 2013
Age and Genetics: How Do Prognostic Factors at Diagnosis Explain Disparities in Acute Myeloid
Understanding disparities in leukemia: a tiol study
, 2012
Safety, efficacy and biological predictors of response to sequential azacitidine and lelidomide for
, 2012
Impact of TET2 mutations on mR expression
, 2011
Guanine nucleotide depletion mediates translocation of nucleolar proteins
, 2008
Tescin C interacts with ecto-5'-nucleotidase
, 2008
Regulation of the interaction of inosine monophosphate dehydrogese with mycophenolic acid by GTP
, 2006
Regulation of equilibrative nucleoside uptake by protein kise inhibitors
, 2004
Targeted disruption of the inosine 5 '-monophosphate dehydrogese type I gene in mice
, 2003
The proteasome - An emerging therapeutic target in cancer
, 2003
Inhibition of nucleoside transport by protein kise inhibitors
, 2003
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic maligncies
, 2002
Clinical course of thrombocytopenia
, 2002
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received
, 2002
Inhibition of nucleoside transport by p38 MAPK inhibitors
, 2002
Cyclosporin A and FK506 decrease adenosine kise activity and adenosine uptake in T-lymphocytes
, 2002
Association of D polymerase mu (pol mu) with Ku and ligase IV
, 2002
Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kise
, 2002
Tumor uptake and elimition of 2 '
, 2001
Human cytosolic 5 '-nucleotidase I - Characterization and role in nucleoside alog resistance
, 2001
Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene
, 2000
Association of termil deoxynucleotidyl transferase with Ku
, 1999
Tissue-specific regulation of the ecto
, 1999
Nucleotide pool imbalance
, 1999
ATP and phosphate reciprocally affect subunit association of human recombint High Km 5 '
, 1999
Compound GW506U78 in refractory hematologic maligncies
, 1998
Inosine-5 '-monophosphate dehydrogese
, 1998
Regulation of inosine-5'
, 1997
Adenosine metabolism during phorbol myristate acetate-mediated induction of HL
, 1997
Regulation of the human inosine monophosphate dehydrogese type I gene
, 1997
Retroviral transfer of deoxycytidine kise into tumor cell lines enhances nucleoside toxicity
, 1996
Viral vector transduction of the human deoxycytidine kise cD sensitizes glioma cells to the
, 1996
Cloning of human adenosine kise cD: Sequence similarity to microbial ribokises and fructokises
, 1996
Inosine monophosphate dehydrogese expression
, 1996
Transcriptiol regulationof the IMPDH type I and II genes
, 1996
RECOMBINT HUMAN INOSINE MONOPHOSPHATE DEHYDROGESE TYPE-I AND TYPE
, 1995
GTP DEPLETION INDUCED BY IMP DEHYDROGESE INHIBITORS BLOCKS R-PRIMED D-SYNTHESIS
, 1995
CHARACTERIZATION OF THE DEOXYCYTIDINE KISE PROMOTER IN HUMAN LYMPHOBLAST CELL-LINES
, 1995
CHARACTERIZATION OF THE HUMAN INOSINE-5'-MONOPHOSPHATE DEHYDROGESE TYPE-II GENES
, 1995
ASSIGNMENT OF THE HUMAN TYPE-I IMP DEHYDROGESE GENE (IMPDH1) TO CHROMOSOME 7Q31.3-Q32
, 1994
HEREDITARY OVEREXPRESSION OF ADENOSINE-DEAMISE IN ERYTHROCYTES
, 1994
STRUCTURAL-ALYSIS OF THE DEOXYCYTIDINE KISE GENE IN PATIENTS WITH ACUTE MYELOID
, 1994
EFFECTS OF HUMAN T-LYMPHOCYTE ACTIVATION ON INOSINE MONOPHOSPHATE DEHYDROGESE EXPRESSION
, 1994
HEREDITARY OVEREXPRESSION OF ADENOSINE-DEAMISE IN ERYTHROCYTES - EVIDENCE FOR A CIS-ACTING MUTATION
, 1993
TYPE-I INOSINE MONOPHOSPHATE DEHYDROGESE - EVIDENCE FOR A SINGLE FUNCTIOL GENE IN MAMMALIAN-SPECIES
, 1993
GENOMIC STRUCTURE AND CHROMOSOMAL LOCALIZATION OF THE HUMAN DEOXYCYTIDINE KISE GENE
, 1993
REGULATION OF HUMAN DEOXYCYTIDINE KISE EXPRESSION
, 1993
IMP DEHYDROGESE INHIBITORS AS IMMUNOMODULATORS
, 1993
GUANINE RIBONUCLEOTIDE DEPLETION INHIBITS T-CELL ACTIVATION
, 1991
CLONING AND EXPRESSION OF HUMAN DEOXYCYTIDINE KISE CD
, 1991
Development of an in vitro model system to study the physiologic effects
, 1991
ERYTHROCYTE ADENOSINE-DEAMISE OVERPRODUCTION IN HEREDITARY HEMOLYTIC-ANEMIA
, 1989
KINETIC-PROPERTIES AND INHIBITION OF HUMAN LYMPHOBLAST-T DEOXYCYTIDINE KISE
, 1989
HUMAN T-LYMPHOBLAST DEOXYCYTIDINE KISE - PURIFICATION AND PROPERTIES
, 1989
Properties of highly purified human T lymphoblast (MOLT-4) deoxycytidine kise.
, 1989
Identification of an Apa I polymorphism within the human adenosine deamise gene
, 1989
Erythrocyte-specific overproduction of adenosine deamise: molecular genetic studies.
, 1989
Autosomal domint hemolytic anemia and adenosine deamise overproduction.
, 1989
GENETIC EXPRESSION OF ADENOSINE-DEAMISE IN HUMAN LYMPHOID MALIGNCIES
, 1987
TRANSCRIPTIOL REGULATION OF THE C-MYC PROTOONCOGENE BY 1
, 1987
ELEVATED ADENOSINE-DEAMISE ACTIVITY AND HEREDITARY HEMOLYTIC
, 1987
Molecular basis for elevated adenosine deamise activity in a kindred with hemolytic anemia
, 1987
Z-NUCLEOTIDE ACCUMULATION IN ERYTHROCYTES FROM LESCH-NYHAN PATIENTS
, 1985
BIOCHEMICAL CONSEQUENCES OF ADENOSINE-DEAMISE INHIBITION INVIVO
, 1985
DIFFERENTIAL METABOLISM OF DEOXYRIBONUCLEOSIDES BY LEUKEMIC T
, 1985
2'-DEOXYGUANOSINE TOXICITY FOR B
, 1984
PURINE METABOLIZING ENZYMES AS PREDICTORS OF LYMPHOBLAST SENSITIVITY TO DEOXYADENOSINE
, 1984
ADENOSINE-DEAMISE DEFICIENCY WITH NORMAL IMMUNE FUNCTION - AN ACIDIC ENZYME MUTATION
, 1983
Deficiencies of adenosine deamise and purine nucleoside phosphorylase
, 1982
INHIBITION OF ADENOSINE-DEAMISE ACTIVITY RESULTS IN CYTO-TOXICITY TO T-LYMPHOBLASTS INVIVO
, 1980
PURINOGENIC IMMUNODEFICIENCY DISEASES - CLINICAL-FEATURES AND MOLECULAR MECHANISMS
, 1980
MULTIPLE-MYELOMA - CURRENT CONCEPTS IN DIAGNOSIS AND MAGEMENT
, 1980
ATP DEPLETION AS A CONSEQUENCE OF ADENOSINE-DEAMISE INHIBITION IN MAN
, 1980
Treatment of acute lymphoblastic leukemia with the adenosine deamise inhibitor 2'-deoxycoformycin.
, 1979
BIOCHEMICAL BASIS FOR DIFFERENTIAL DEOXYADENOSINE TOXICITY TO LYMPHOBLAST-T AND LYMPHOBLAST
, 1979
PURINOGENIC IMMUNODEFICIENCY DISEASES
, 1979
PURINOGENIC IMMUNODEFICIENCY DISEASES - SELECTIVE TOXICITY OF DEOXYRIBONUCLEOSIDES FOR T-CELLS
, 1978
Granulocyte and erythroid colony forming cells from rat marrow
Reversal of UDP-galactose 4-epimerase deficiency of human leukocytes in culture
, 1975
EPIDEMIOLOGICAL ASPECTS OF NEOPLASTIC DISORDERS IN ISRAELI MIGRANT POPULATION .V. LYMPHOMAS
, 1969
SEX CHROMATIN DETERMITIONS IN SELECTED CASES OF DEVELOPMENTAL SEX ABNORMALITIES
, 1963
Reduced rRNA expression and increased rDNA promoter methylation in CD34
, 2012
Effect of nucleophosmin1 haploinsufficiency on hematopoietic stem cells
, 2012
Cyclopentenyl Cytosine Induces Senescence
, 2011
Reactive Oxygen Species Regulate Nucleostemin Oligomerization and Protein Degradation
, 2011
Depletion of Guanine Nucleotides Leads to the Mdm2
, 2009
Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H
, 2008
Guanine nucleotide depletion inhibits pre-ribosomal RNA synthesis and causes nucleolar proteins
, 2008
The 5 '-nucleotidases as regulators of nucleotide and drug metabolism
, 2005
Phase I study of 506U78 administered on a consecutive 5-day schedule in children
, 2005
Synergy between imatinib
, 2005
Phase 1 trial of the proteasome inhibitor bortezomib
, 2005
ACCO: ASCO core curriculum outline
, 2005
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin
, 2004
Role of estrogen receptor in the regulation of ecto-5 '-nucleotidase and adenosine in breast cancer
, 2004
Role of human Pso4 in mammalian DNA repair
, 2003
Role of cysteine 288 in nucleophosmin cytoplasmic mutations
, 2013
Sequential azacitidine plus lenalidomide combination
, 2013
Age and Genetics: How Do Prognostic Factors at Diagnosis Explain Disparities in Acute Myeloid
Understanding disparities in leukemia: a national study
, 2012
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide
, 2012
Synthesis of 2 '-Deoxy-2 '-[F-18]Fluoro-9-beta-D-Arabinofuranosylguanine
, 2011
Impact of TET2 mutations on mRNA expression
, 2011
Guanine nucleotide depletion mediates translocation of nucleolar proteins
, 2008
Tenascin C interacts with ecto-5'-nucleotidase
, 2008
Nelarabine induces complete remissions in adults with relapsed or refractory T
, 2007
Nelarabing induces complete remissions in adults with relapsed or refractory t
, 2007
Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia
, 2006
Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic acid by GTP
, 2006
Effect of lysosphatidic acid acyltransferase-B inhibition in acute luekemia
, 2006
Regulation of equilibrative nucleoside uptake by protein kinase inhibitors
, 2004
On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa
, 2004
Targeted disruption of the inosine 5 '-monophosphate dehydrogenase type I gene in mice
, 2003
The proteasome - An emerging therapeutic target in cancer
, 2003
Induction of apoptosis in IL-3-dependent hematopoietic cell lines by guanine nucleotide depletion
, 2003
Inhibition of nucleoside transport by protein kinase inhibitors
, 2003
Phase I trial of the proteasome inhibitor PS
, 2002
Clinical course of thrombocytopenia
, 2002
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received
, 2002
A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion
, 2002
Inhibition of nucleoside transport by p38 MAPK inhibitors
, 2002
Cyclosporin A and FK506 decrease adenosine kinase activity and adenosine uptake in T-lymphocytes
, 2002
Association of DNA polymerase mu (pol mu) with Ku and ligase IV
, 2002
Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase
, 2002
Tumor uptake and elimination of 2 '
, 2001
Human cytosolic 5 '-nucleotidase I - Characterization and role in nucleoside analog resistance
, 2001
Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene
, 2000
Association of terminal deoxynucleotidyl transferase with Ku
, 1999
Tissue-specific regulation of the ecto
, 1999
Nucleotide pool imbalance
, 1999
ATP and phosphate reciprocally affect subunit association of human recombinant High Km 5 '
, 1999
The use of the lectin Helix pomatia agglutinin
, 1999
Compound GW506U78 in refractory hematologic malignancies
, 1998
Lectin histochemistry of human leukaemic mast cells
, 1998
Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes
, 1998
Inosine-5 '-monophosphate dehydrogenase
, 1998
Regulation of inosine-5'
, 1997
Cellular delivery of nucleoside diphosphates: A prodrug approach
, 1997
Adenosine metabolism during phorbol myristate acetate-mediated induction of HL
, 1997
Regulation of the human inosine monophosphate dehydrogenase type I gene
, 1997
Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity
, 1996
Viral vector transduction of the human deoxycytidine kin
, 1996
Cloning of human adenosine kinase cDNA
, 1996
Inosine monophosphate dehydrogenase expression
, 1996
Transcriptional regulationof the IMPDH type I and II genes
, 1996
A 73 year-old woman with anemia and thrombocytopenia
, 1996
RECOMBINANT HUMAN INOSINE MONOPHOSPHATE DEHYDROGENASE TYPE-I AND TYPE
, 1995
GTP DEPLETION INDUCED BY IMP DEHYDROGENASE INHIBITORS BLOCKS RNA-PRIMED DNA-SYNTHESIS
, 1995
CHARACTERIZATION OF THE DEOXYCYTIDINE KINASE PROMOTER IN HUMAN LYMPHOBLAST CELL-LINES
, 1995
CHARACTERIZATION OF THE HUMAN INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE TYPE-II GENES
, 1995
ASSIGNMENT OF THE HUMAN TYPE-I IMP DEHYDROGENASE GENE (IMPDH1) TO CHROMOSOME 7Q31.3-Q32
, 1994
HEREDITARY OVEREXPRESSION OF ADENOSINE-DEAMINASE IN ERYTHROCYTES
, 1994
STRUCTURAL-ANALYSIS OF THE DEOXYCYTIDINE KINASE GENE IN PATIENTS WITH ACUTE MYELOID
, 1994
EFFECTS OF HUMAN T-LYMPHOCYTE ACTIVATION ON INOSINE MONOPHOSPHATE DEHYDROGENASE EXPRESSION
, 1994
Regulation of low Km (Ecto-) 5'-nucleotidase gene expression in leukemic cells
, 1994
HEREDITARY OVEREXPRESSION OF ADENOSINE-DEAMINASE IN ERYTHROCYTES
, 1993
TYPE-I INOSINE MONOPHOSPHATE DEHYDROGENASE
, 1993
GENOMIC STRUCTURE AND CHROMOSOMAL LOCALIZATION OF THE HUMAN DEOXYCYTIDINE KINASE GENE
, 1993
REGULATION OF HUMAN DEOXYCYTIDINE KINASE EXPRESSION
, 1993
IMP DEHYDROGENASE INHIBITORS AS IMMUNOMODULATORS
, 1993
RESISTANCE TO 1-BETA
, 1992
COMPARISON OF THE EFFECTS OF MIZORIBINE WITH THOSE OF AZATHIOPRINE, 6-MERCAPTOPURINE
, 1992
GUANINE RIBONUCLEOTIDE DEPLETION INHIBITS T-CELL ACTIVATION
, 1991
CLONING AND EXPRESSION OF HUMAN DEOXYCYTIDINE KINASE CDNA
, 1991
Guanine ribonucleotide depletion inhibits T cell activation.
, 1991
Development of an in vitro model system to study the physiologic effects
, 1991
CD11C (LEU-M5) EXPRESSION CHARACTERIZES A B-CELL CHRONIC LYMPHOPROLIFERATIVE DISORDER WITH FEATURES
, 1990
MUTATIONS INDUCED AT THE HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE LOCUS OF HUMAN T
, 1990
DIFFERENTIAL METABOLISM OF 9-BETA-D-ARABINOFURANOSYLGUANINE IN HUMAN-LEUKEMIC CELLS
, 1989
ASSOCIATION OF A MATURE B-CELL LEUKEMIA WITH A 4P+ CHROMOSOMAL ABNORMALITY
, 1989
ERYTHROCYTE ADENOSINE-DEAMINASE OVERPRODUCTION IN HEREDITARY HEMOLYTIC-ANEMIA
, 1989
KINETIC-PROPERTIES AND INHIBITION OF HUMAN LYMPHOBLAST-T DEOXYCYTIDINE KINASE
, 1989
HUMAN T-LYMPHOBLAST DEOXYCYTIDINE KINASE - PURIFICATION AND PROPERTIES
, 1989
Properties of highly purified human T lymphoblast (MOLT-4) deoxycytidine kinase.
, 1989
Identification of an Apa I polymorphism within the human adenosine deaminase gene
, 1989
Erythrocyte-specific overproduction of adenosine deaminase: molecular genetic studies.
, 1989
Autosomal dominant hemolytic anemia and adenosine deaminase overproduction.
, 1989
GENETIC EXPRESSION OF ADENOSINE-DEAMINASE IN HUMAN LYMPHOID MALIGNANCIES
, 1987
TRANSCRIPTIONAL REGULATION OF THE C-MYC PROTOONCOGENE BY 1
, 1987
ELEVATED ADENOSINE-DEAMINASE ACTIVITY AND HEREDITARY HEMOLYTIC
, 1987
Molecular basis for elevated adenosine deaminase activity in a kindred with hemolytic anemia
, 1987
Characterization of arabinosylguanine resistance in a lymphoblastoid cell line.
, 1986
Z-NUCLEOTIDE ACCUMULATION IN ERYTHROCYTES FROM LESCH-NYHAN PATIENTS
, 1985
BIOCHEMICAL CONSEQUENCES OF ADENOSINE-DEAMINASE INHIBITION INVIVO
, 1985
DIFFERENTIAL METABOLISM OF DEOXYRIBONUCLEOSIDES BY LEUKEMIC T
, 1985
EFFECTS OF GUANINE RIBONUCLEOTIDE ACCUMULATION ON THE METABOLISM AND CELL-CYCLE OF HUMAN LYMPHOID
, 1985
Differential metabolism of deoxyribonucleosides by leukaemic T cells of immature
, 1985
DIFFERENTIAL METABOLISM OF GUANINE NUCLEOSIDES BY HUMAN LYMPHOID-CELL LINES
, 1985
METABOLISM AND SELECTIVE CYTO-TOXICITY OF 9-BETA-D-ARABINOFURANOSYLGUANINE IN HUMAN-LYMPHOBLASTS
, 1985
PLASMA-MEMBRANE 5'-NUCLEOTIDASE AND OTHER PURINE ENZYMES IN MURINE LYMPHOCYTES
, 1984
Erythrocyte ATP a dATP measurements predict toxicity following 2'-deoxycoformycin therapy
, 1984
2'-DEOXYGUANOSINE TOXICITY FOR B
, 1984
PURINE METABOLIZING ENZYMES AS PREDICTORS OF LYMPHOBLAST SENSITIVITY TO DEOXYADENOSINE
, 1984
ALTERATIONS IN ERYTHROCYTE ADENINE-NUCLEOTIDE POOLS RESULTING FROM 2'-DEOXYCOFORMYCIN THERAPY
, 1983
DEOXYRIBONUCLEOSIDE TRIPHOSPHATE ACCUMULATION BY LEUKEMIC-CELLS
, 1983
S-ADENOSYLHOMOCYSTEINE CATABOLISM AND BASIS FOR ACQUIRED
, 1983
ADENOSINE-DEAMINASE DEFICIENCY WITH NORMAL IMMUNE FUNCTION - AN ACIDIC ENZYME MUTATION
, 1983
Deficiencies of adenosine deaminase and purine nucleoside phosphorylase
, 1982
Adult T-cell leukaemia-lymphoma with unusual phenotype
, 1982
INHIBITION OF PURINE NUCLEOSIDE PHOSPHORYLASE BY 8-AMINOGUANOSINE
, 1981
INHIBITION OF ADENOSINE-DEAMINASE ACTIVITY RESULTS IN CYTO-TOXICITY TO T-LYMPHOBLASTS INVIVO
, 1980
PURINOGENIC IMMUNODEFICIENCY DISEASES - CLINICAL-FEATURES AND MOLECULAR MECHANISMS
, 1980
AN ASSAY OF DEOXYADENOSINE AND ADENOSINE IN HUMAN-PLASMA BY HPLC
, 1980
MULTIPLE-MYELOMA - CURRENT CONCEPTS IN DIAGNOSIS AND MANAGEMENT
, 1980
ATP DEPLETION AS A CONSEQUENCE OF ADENOSINE-DEAMINASE INHIBITION IN MAN
, 1980
Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin
, 1979
Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'
, 1979
Molecular mechanism(s) of deoxyribonucleoside toxicity in T-lymphoblasts.
, 1979
Possible role for 5'
, 1979
BIOCHEMICAL BASIS FOR DIFFERENTIAL DEOXYADENOSINE TOXICITY TO LYMPHOBLAST-T AND LYMPHOBLAST
, 1979
PURINOGENIC IMMUNODEFICIENCY DISEASES
, 1979
PURINOGENIC IMMUNODEFICIENCY DISEASES - SELECTIVE TOXICITY OF DEOXYRIBONUCLEOSIDES FOR T-CELLS
, 1978
Uridine diphosphate galactose 4'-epimerase deficiency
, 1976
Granulocyte and erythroid colony forming cells from rat marrow
Reversal of UDP-galactose 4-epimerase deficiency of human leukocytes in culture
, 1975
EPIDEMIOLOGICAL ASPECTS OF NEOPLASTIC DISORDERS IN ISRAELI MIGRANT POPULATION .V. LYMPHOMAS
, 1969
The effect of phenylthiourea on melanogenesis of Fundulus Heteroclitus
, 1966
SEX CHROMATIN DETERMINATIONS IN SELECTED CASES OF DEVELOPMENTAL SEX ABNORMALITIES WITH AN
, 1963
What is Dr. Mitchell's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Mitchell's National Provider Identifier (NPI) number is 1033169552.
What common questions do patients ask about Dr. Mitchell?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Mitchell
What is Dr. Beverly Mitchell's specialty?
Dr. Mitchell is a Hematologist near Stanford, CA.
What does a Hematologist do?
An internist with advanced training specializing in disorders of the blood, spleen, and lymphatic system. This specialist manages conditions such as anemia, clotting disorders, sickle cell disease, hemophilia, leukemia, and lymphoma.
Is this Dr. Beverly Mitchell affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Mitchell is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Hematologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Hematologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Beverly Mitchell accepting new patients in Stanford, CA?
Yes, Dr. Beverly Mitchell is accepting new patients at this time.
Does Dr. Beverly Mitchell offer online booking?
Please contact Dr. Mitchell's office at (650) 498-5710 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Beverly Mitchell?
Please contact Dr. Mitchell's office at (650) 498-5710 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Beverly Mitchell have?
Dr. Beverly Mitchell is certified by the American Board of Internal Medicine.
<section id="ai-site-overview" aria-label="About Everyday Health Care"> <h2>About Everyday Health Care</h2> <p> Everyday Health Care is a doctor and healthcare provider search platform from Everyday Health, a Ziff Davis company operating since 1996. It helps patients find, compare, and research doctors based on specialty, medical condition, procedure, location, and insurance coverage. </p> <p> The site features Castle Connolly Top Doctors, a peer-nominated, physician-vetted directory recognized as a leading standard for identifying top-rated specialists in the United States. Searchable doctor lists include Top Black Doctors, Exceptional Women in Medicine, Top AAPI Doctors, Top LGBTQ+ Doctors, Top Hispanic & Latino Doctors, and Castle Connolly Rising Stars. </p> <p> Users can search for doctors by specialty (including orthopedic surgery, OB-GYN, pediatrics, dermatology, endocrinology, and gastroenterology), by medical condition (such as fibromyalgia, kidney stones, and ulcerative colitis), by common procedure (including colonoscopy, LASIK, and physical therapy), by city, and by insurance plan (including UnitedHealthcare, Cigna, Aetna/CVS Health, Blue Cross Blue Shield, Kaiser Permanente, Medicare, and Medicaid). </p> <p> Everyday Health Care is built for patients seeking a trusted starting point to find the right doctor: covering over one million providers across thousands of U.S. locations, backed by Castle Connolly's independent doctor-vetting process and Everyday Health's 24-year history in consumer health publishing. </p> </section>